Open Payments

Baystate Medical Center

Type
Teaching hospital
Where
SPRINGFIELD, MA
Medicare CCN
220077
Received
$477,810 in 88 records, 2022 ($73,139 general, $404,671 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment20$73,139
2022Research payment68$404,671

By company

CompanyRecordsAmountYears
Eli Lilly and Company1$125,0002022
Medtronic, Inc.17$113,6272022
GlaxoSmithKline, LLC.9$41,7752022
Rhythm Pharmaceuticals, Inc.16$41,6702022
Insmed, Inc.9$28,9252022
Bio-Rad Laboratories, Inc.1$24,8002022
Takeda Pharmaceuticals U.S.A., Inc.7$23,6002022
Genentech, Inc.1$17,6612022
Chiesi USA, Inc.1$14,8502022
GENZYME CORPORATION6$10,6922022
Teleflex LLC1$6,1712022
Medline Industries LP1$5,7902022
BIOTRONIK INC.2$5,6502022
KARL STORZ Endoscopy-America1$3,4942022
Roche Diagnostics Corporation4$3,4802022
Hoffmann-La Roche Limited1$2,9702022
Abbott Laboratories2$2,5702022
Bolton Medical Inc1$2,0002022
Edwards Lifesciences Corporation1$1,2492022
Celgene Corporation1$8502022
Stryker Corporation3$5482022
Arrow International, Inc.1$3852022
NeuroLogica Corporation, a Samsung Company1$502022

By nature of payment

NatureRecordsAmount
Research payment68$404,671
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$24,800
Grant2$20,000
Debt forgiveness9$16,138
Long term medical supply or device loan2$7,420
Travel and Lodging2$3,110
Space rental or facility fees (teaching hospital only)1$1,250
Food and Beverage3$419

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Teleflex LLC$6,171Long term medical supply or device loanIn-kind items and servicesWECK Device, SURGICAL2022
2022-12-31Medline Industries LP$5,790Debt forgivenessCash or cash equivalent2022
2022-12-31KARL STORZ Endoscopy-America$3,494Debt forgivenessIn-kind items and services2022
2022-12-31Edwards Lifesciences Corporation$1,249Long term medical supply or device loanIn-kind items and servicesHemoSphere Device, Hemodynamic Monitoring2022
2022-12-31Stryker Corporation$304Debt forgivenessCash or cash equivalent2022
2022-12-31Stryker Corporation$150Debt forgivenessCash or cash equivalent2022
2022-12-31Stryker Corporation$93Debt forgivenessCash or cash equivalent2022
2022-12-04GlaxoSmithKline, LLC.$4,175Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-11-23Insmed, Inc.$4,000Research paymentCash or cash equivalentA Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr2022
2022-11-23Insmed, Inc.$350Research paymentCash or cash equivalentA Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr2022
2022-11-21GENZYME CORPORATION$2,372Research paymentCash or cash equivalentFabry LSD Data Registry2022
2022-11-18Celgene Corporation$850Research paymentCash or cash equivalentPhase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-2022
2022-11-03Medtronic, Inc.$2,600Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-10-31Genentech, Inc.$17,661Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2022
2022-10-25Medtronic, Inc.$22,848Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-10-21Takeda Pharmaceuticals U.S.A., Inc.$10,000Research paymentCash or cash equivalentPHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC 2022
2022-10-21GlaxoSmithKline, LLC.$6,009Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-10-21Takeda Pharmaceuticals U.S.A., Inc.$4,000Research paymentCash or cash equivalentPHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC 2022
2022-10-21Takeda Pharmaceuticals U.S.A., Inc.$3,000Research paymentCash or cash equivalentPHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC 2022
2022-10-21Takeda Pharmaceuticals U.S.A., Inc.$3,000Research paymentCash or cash equivalentPHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC 2022
2022-10-21GlaxoSmithKline, LLC.$2,000Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-10-21Takeda Pharmaceuticals U.S.A., Inc.$1,950Research paymentCash or cash equivalentPHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC 2022
2022-10-21Takeda Pharmaceuticals U.S.A., Inc.$1,300Research paymentCash or cash equivalentPHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC 2022
2022-10-21Takeda Pharmaceuticals U.S.A., Inc.$350Research paymentCash or cash equivalentPHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC 2022
2022-10-19Insmed, Inc.$17,900Research paymentCash or cash equivalentA Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr2022
2022-10-19Insmed, Inc.$2,500Research paymentCash or cash equivalentA Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr2022
2022-10-12Rhythm Pharmaceuticals, Inc.$4,000Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-10-12Rhythm Pharmaceuticals, Inc.$1,300Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-10-12Rhythm Pharmaceuticals, Inc.$1,300Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-10-12Rhythm Pharmaceuticals, Inc.$650Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-10-12Rhythm Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-09-30BIOTRONIK INC.$3,350Debt forgivenessCash or cash equivalent2022
2022-09-27Medtronic, Inc.$741Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-09-26GENZYME CORPORATION$1,787Research paymentCash or cash equivalentPompe LSD Data Registry2022
2022-09-26GENZYME CORPORATION$715Research paymentCash or cash equivalentFabry LSD Data Registry2022
2022-09-12Eli Lilly and Company$125,000Research paymentCash or cash equivalent2022
2022-08-31Medtronic, Inc.$15,546Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-08-24GlaxoSmithKline, LLC.$8,000Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-08-24GlaxoSmithKline, LLC.$5,087Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-08-15GENZYME CORPORATION$3,055Research paymentCash or cash equivalentFabry LSD Data Registry2022
2022-08-15GENZYME CORPORATION$260Research paymentCash or cash equivalentPompe LSD Data Registry2022
2022-08-01Medtronic, Inc.$5,757Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-08-01Medtronic, Inc.$5,757Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-07-29Arrow International, Inc.$385Debt forgivenessCash or cash equivalent2022
2022-07-25Rhythm Pharmaceuticals, Inc.$435Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0222022
2022-07-18Rhythm Pharmaceuticals, Inc.$4,948Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0142022
2022-07-05NeuroLogica Corporation, a Samsung Company$50Food and BeverageCash or cash equivalent2022
2022-06-27Roche Diagnostics Corporation$1,754Travel and LodgingIn-kind items and servicesBCM for cobas 8100 Device, Core Lab2022
2022-06-27Roche Diagnostics Corporation$157Food and BeverageIn-kind items and servicesBCM for cobas 8100 Device, Core Lab2022
2022-06-24Medtronic, Inc.$10,000GrantCash or cash equivalent2022
2022-06-17Medtronic, Inc.$14,027Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-06-15Rhythm Pharmaceuticals, Inc.$15,000Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-06-15Rhythm Pharmaceuticals, Inc.$3,000Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-06-15Rhythm Pharmaceuticals, Inc.$3,000Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-06-15Rhythm Pharmaceuticals, Inc.$2,500Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-06-15Rhythm Pharmaceuticals, Inc.$425Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-06-15Rhythm Pharmaceuticals, Inc.$350Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-06-02Rhythm Pharmaceuticals, Inc.$1,662Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0222022
2022-05-20Medtronic, Inc.$850Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-05-20Medtronic, Inc.$850Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-05-20Medtronic, Inc.$802Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-05-20Medtronic, Inc.$802Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-05-16Medtronic, Inc.$10,000GrantCash or cash equivalent2022
2022-05-12Insmed, Inc.$1,375Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2022
2022-05-12Insmed, Inc.$450Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2022
2022-05-10Insmed, Inc.$1,250Space rental or facility fees (teaching hospital only)In-kind items and services2022
2022-05-05Bolton Medical Inc$2,000Research paymentCash or cash equivalentRelayPro-A IP-0015-16 Device, DeviceRelayPro-A IP-0015-162022
2022-04-27Medtronic, Inc.$10,298Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-04-27Medtronic, Inc.$10,298Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-04-19BIOTRONIK INC.$2,300Research paymentCash or cash equivalentOrsiro Mission Device, Cardiology/Vascular DiseasesBIOFLOW-VII2022
2022-04-11GlaxoSmithKline, LLC.$2,534Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-04-11Roche Diagnostics Corporation$1,356Travel and LodgingIn-kind items and servicescobas 8000 Core Unit Device, Core Lab2022
2022-04-11Roche Diagnostics Corporation$211Food and BeverageIn-kind items and servicescobas 8000 Core Unit Device, Core Lab2022
2022-04-05Insmed, Inc.$650Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2022
2022-04-05Insmed, Inc.$450Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2022
2022-04-04Chiesi USA, Inc.$14,850Research paymentCash or cash equivalentCUROSURF Drug, NEONATOLOGYA STUDY IN PRETERM NEONATES WITH RDS TO COMPARE CUROSURF ADMINISTRATION THROUGH LISA AND CONVENTIONAL ADMINISTRATION (LI2022
2022-03-31Rhythm Pharmaceuticals, Inc.$650Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0142022
2022-03-29Medtronic, Inc.$1,225Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-03-29Medtronic, Inc.$1,225Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-03-22Hoffmann-La Roche Limited$2,970Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2022
2022-03-22Abbott Laboratories$1,285Debt forgivenessCash or cash equivalentARCHITECT Device, Core Diagnostics2022
2022-03-22Abbott Laboratories$1,285Debt forgivenessCash or cash equivalentARCHITECT Device, Core Diagnostics2022
2022-03-16Rhythm Pharmaceuticals, Inc.$1,950Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0222022
2022-03-09Bio-Rad Laboratories, Inc.$24,800Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesBioPlex 2200 Device, BioPlex2022
2022-02-22GlaxoSmithKline, LLC.$4,508Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-02-22GENZYME CORPORATION$2,502Research paymentCash or cash equivalentFabry LSD Data Registry2022
2022-02-14GlaxoSmithKline, LLC.$4,934Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022
2022-01-24GlaxoSmithKline, LLC.$4,526Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Hampden CountySpringfield city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Springfield, MA, county Hampden County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Springfield, MA
County
Hampden County, MA
State
Massachusetts
Population B01003154,749462,8157,044,056
Population, 2020 census P1155,929465,8257,029,917
Median age B0100233.740.040.0
Under 18 B0100124.2%20.9%19.4%
65 and over B0100113.2%18.3%17.9%
Households B1100157,772184,4712,785,042
Foreign born B0500210.5%9.4%18.0%
Median household income B19013$52,656$71,306$103,960
Median family income B19113$66,045$91,397$131,675
Per capita income B19301$27,337$38,219$57,897
Poverty rate B1700125.8%16.3%10.0%
Unemployment rate B230258.7%6.0%5.2%
Civilian labor force B2302569,390226,7713,911,446
Mean commute (minutes) B0801320.222.729.1
Bachelor's degree or higher B1500320.5%29.3%47.3%
Housing units B2500162,217197,5913,030,406
Owner-occupied B2500349.6%62.2%62.5%
Renters B2500350.4%37.8%37.5%
Median home value B25077$245,000$298,800$562,100
Median gross rent B25064$1,144$1,136$1,762
White, not Hispanic B0300227.8%59.3%66.6%
Black B0300217.5%7.6%6.4%
Hispanic or Latino B0300248.6%27.0%13.3%
Asian B030022.7%2.5%7.3%
American Indian and Alaska Native B030020.1%0.0%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Springfield, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.